Table 3.

Summary of relative risk reduction of non-vertebral fractures (NVF) and clinical fractures (CF) using cumulative dose and post-hoc meta-analysis

Study	Patients, n	Comparator	High-dose ACE (>10.8 mg)
Harris et al22	8,710	Placebo (BONE study)	Major NVF: 34.4% (P=0.032) All NVF: 29.9% (P=0.041) CF: 28.8% (P=0.010) NVF: 38.0% (P=0.038) NVF: 30.0% (P=0.04)
Cranney et al23	9,753	Low	CF: 29.0% (P=0.01)
Sebba et al24	8,710	Placebo

Abbreviations: ACE, annual accumulative dose; BONE, Oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe.